The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment
Open accessAbstract
At least 2.3 million people in the U.S. have an opioid use disorder, less than 40% of whom receive evidence-based treatment. Buprenorphine used as part of medication-assisted treatment has high potential to address this gap because of its approval for use in non-specialty outpatient settings, effectiveness at promoting abstinence, and cost effectiveness. However, less than 4% of licensed physicians are approved to prescribe buprenorphine for opioid use disorder, and approximately 47% of counties lack a buprenorphine-waivered physician. Existing policies contribute to workforce barriers to buprenorphine provision and access. Providers are reticent to prescribe buprenorphine because of workforce barriers, such as (1) insufficient training and education on opioid use disorder treatment, (2) lack of institutional and clinician peer support, (3) poor care coordination, (4) provider stigma, (5) inadequate reimbursement from private and public insurers, and (6) regulatory hurdles to obtain the waiver needed to prescribe buprenorphine in non-addiction specialty treatment settings. Policy pathways to addressing these provider workforce barriers going forward include providing free and easy-to-access education for providers about opioid use disorders and medication-assisted treatment, eliminating buprenorphine waiver requirements for those licensed to prescribe controlled substances, enforcing insurance parity requirements, requiring coverage of evidence-based medication-assisted treatment as essential health benefits, and providing financial incentives for care coordination across healthcare professional types-including behavioral health counselors and other non-physicians in specialty and non-specialty settings. SUPPLEMENT INFORMATION: This article is part of a supplement entitled The Behavioral Health Workforce: Planning, Practice, and Preparation, which is sponsored by the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration of the U.S. Department of Health and Human Services.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increases in drug and opioid-involved overdose deaths – United States, 2010-2015
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm655051e1 · Cited by 2,194
Increases in drug and opioid overdose deaths — United States, 2000–2014
Rudd, R. A., Aleshire, N., Zibbell, J. E., & Gladden, R. M. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6450a3 · Cited by 1,859 · cited 4×
“Also under the ACA, plans are required to cover ten essential health benefits (EHBs), including: (1) mental health and substance use disorder services, and (2) a prescription drug Haffajee et al.”
BackgroundInfluentialSordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
van Boekel, L. C., Brouwers, E. P. M., van Weeghel, J., & Garretsen, H. F. L. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.02.018 · Cited by 1,810
Vital signs: changes in opioid prescribing in the United States, 2006-2015.
Guy, G. P., Zhang, K., Bohm, M. K., Losby, J., Lewis, B., Young, R., Murphy, L. B., & Dowell, D. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6626a4 · Cited by 1,117
Amato, L., Davoli, M., A.Perucci, C., Ferri, M., Faggiano, F., & P. Mattick, R. (2005) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2005.02.007 · Cited by 567
Treatment of opioid-use disorders
Schuckit, M. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1604339 · Cited by 540
Jones, C. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.01.007 · Cited by 517
Hser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455
Initiation into prescription opioid misuse amongst young injection drug users
Lankenau, S. E., Teti, M., Silva, K., Bloom, J. J., Harocopos, A., & Treese, M. (2012) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2011.05.014 · Cited by 440 · cited 2×
“17,75–77 Categories of workforce barriers contributing to buprenorphine underutilization include: (1) insufficient training, education, and experience; (2) lack of institutional and clinician peer support; (3) poor care coordination; (4) provider stigma; (5) inadequate or burdensome reimbursement; and (6) burdensome r…”
Background
Cited by
Stigma as a fundamental hindrance to the United States opioid overdose crisis response
Tsai, A. C., Kiang, M. V., Barnett, M. L., Beletsky, L., Keyes, K. M., McGinty, E. E., Smith, L. R., Strathdee, S. A., Wakeman, S. E., & Venkataramani, A. S. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002969 · Cited by 437
Haffajee, R. L., Lin, L. A., Bohnert, A. S. B., & Goldstick, J. E. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.6373 · Cited by 261
Self-citation
Metadata
- Authors
- Haffajee, R. L., Bohnert, A. S. B., & Lagisetty, P. A.
- Venue
- American Journal of Preventive Medicine
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 54
- Issue
- 6
- Pages
- S230-S242
- ISSN
- 0749-3797 (ISSN-L)
- OpenAlex
- W2803146037
- Cited by
- 252
- References
- 14
- FWCI
- 24.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment. https://app.cochat.ai/papers/10.1016/j.amepre.2017.12.022
- The paper
- Haffajee, R. L., Bohnert, A. S. B., & Lagisetty, P. A. (2018). Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment. American Journal of Preventive Medicine. https://doi.org/10.1016/j.amepre.2017.12.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.